Soligenix Announces Public Offering to Fund Development of Rare Disease Treatments

Soligenix Launches Public Offering to Fund Rare Disease Treatments

Soligenix, Inc., a late-stage biopharmaceutical company dedicated to addressing rare diseases, announces a public offering of 5,555,560 shares of common stock priced at $1.35 per share, along with warrants to purchase an equal number of shares. The offering is anticipated to generate approximately $7.5 million in gross proceeds before expenses, which the company plans to utilize for advancing its research and development initiatives, commercialization efforts, and general corporate purposes. This fundraising effort is crucial for Soligenix as it works on innovative therapies that target unmet medical needs within the rare disease sector.

The offering is set to close around September 29, 2025, subject to customary closing conditions. As part of this public offering, existing warrants from previous funding rounds will be amended to align their exercise price with the current offering price. This strategic move ensures that the company maintains a consistent valuation across its securities while also potentially enhancing investor confidence as it embarks on this fundraising journey. A.G.P./Alliance Global Partners serves as the sole placement agent for this offering, which is conducted under a registration statement on Form S-1 that was filed with the Securities and Exchange Commission (SEC) earlier this month.

The proceeds from the public offering are particularly vital as Soligenix continues to develop its pipeline of treatments for rare diseases, which often receive less attention and funding compared to more common conditions. By securing this additional capital, Soligenix is better positioned to advance its promising therapies through clinical trials and toward commercialization. The company’s commitment to rare disease treatment underscores its role in a niche but critical segment of the biopharmaceutical industry, where innovative solutions can significantly improve patients’ quality of life.

In addition to the public offering, Soligenix is actively engaged in research efforts that target specific rare diseases, including its leading candidate for a treatment addressing gastrointestinal complications associated with acute radiation syndrome. The company's dedication to developing effective therapies illustrates its strategic focus on high-impact areas of medical need.

As the biopharmaceutical landscape evolves, Soligenix remains steadfast in its mission to bring new hope to patients suffering from rare diseases, leveraging both its innovative research capabilities and the financial resources generated through this recent public offering. The company aims to foster advancements that not only contribute to medical science but also provide tangible benefits to those affected by these often-overlooked conditions.